Compare XBIT & DLHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | DLHC |
|---|---|---|
| Founded | 2005 | 1969 |
| Country | United States | United States |
| Employees | N/A | 2300 |
| Industry | Pharmaceuticals and Biotechnology | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 50.9M |
| IPO Year | 2015 | 2012 |
| Metric | XBIT | DLHC |
|---|---|---|
| Price | $1.95 | $3.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 82.6K | 7.7K |
| Earning Date | 11-12-2026 | 12-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,923,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.57 |
| 52 Week Low | $1.80 | $3.38 |
| 52 Week High | $2.73 | $6.88 |
| Indicator | XBIT | DLHC |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 36.10 |
| Support Level | $1.83 | N/A |
| Resistance Level | $2.42 | $4.15 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 45.45 | 0.00 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.